Table 2

Primary and secondary variables per group at start and end of trial and P-values for change within and between groups
Variable  Fish oil  Placebo Between
Baseline End of trial P-value* Baseline End of trial P-value* P-value
PVF 76.7 ± 19.6 82.6 ± 22.6 0.021 77.2 ± 20.5 79.3 ± 22.1 0.210 0.388
Impulse 9.9 ± 3.5 10.2 ± 3.5 0.092 10.0 ± 2.9 10.6 ± 3.4 0.207 0.699
HCPI 16.1 ± 5.4 12.8 ± 6.8 <0.001 17.1 ± 6.4 15.0 ± 6.9 0.013 0.335
NSAID use 1.0 ± 1.4 0.4 ± 0.8 0.017 0.7 ± 1.2 0.4 ± 0.9 0.214 0.740
Locomotion-VAS 3.8 ± 1.9 3.5 ± 2.1 0.489 4.5 ± 1.9 4.0 ± 2.2 0.220 0.354
QOL-VAS 3.6 ± 1.8 2.9 ± 1.8 0.045 3.8 ± 1.8 3.5 ± 1.9 0.301 0.749
Comp. mobility 26.1 ± 4.55 23.1 ± 11.0 0.021 25.9 ± 4.1 24.1 ± 5.7 0.122 0.525
Comp. daily chores 22.7 ± 4.7 19.2 ± 9.5 0.011 21.6 ± 4.2 20.2 ± 5.6 0.339 0.595
Comp. skin/hair 7.9 ± 1.1 6.9 ± 3.0 0.025 7.8 ± 1.6 7.5 ± 2.0 0.424 0.572
Vet. index 2.4 ± 2.4 2.1 ± 2.5 0.096 2.5 ± 2.2 2.7 ± 2.6 0.009 0.196
Owner final (1–5)§ NA 1.3 ± 1.2 NA NA 1.9 ± 1.1 NA 0.029
Group? (1–2)£ NA 1.4 ± 0.5 NA NA 1.7 ± 0.5 NA 0.028

* = P-value of comparing start of trial to end of trial, within group.

 = P-value of comparing change from baseline to end of trial, between groups, except for the last two (“owner final” and “Group?”), where the P-value is the difference between the two group means at end of trial.

 = W−8 was here used as baseline, as owners were asked to not use NSAIDs at W0.

§ = At the end of trial the owners answered a questions on how well the treatment corresponded to their idea of a successful treatment; 1 = corresponded fully, 2 = quite well, 3 = to some parts, 4 = not so well, 5 = not at all.

£ = Owners guessed that their dogs were in 1 = the treatment or in 2 = the placebo group.

Comp. = comparative questionnaire. Values P <0·05 are bolded. NA = data not available.

Hielm-Björkman et al.

Hielm-Björkman et al. BMC Veterinary Research 2012 8:157   doi:10.1186/1746-6148-8-157

Open Data